Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin for Cardioprotection in Breast Cancer Patients Receiving Doxorubicin
NCT07852546Phase 3Not yet recruiting
- Sponsor
- Tanta University
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 3 trial of linagliptin in Cardiotoxicity, sponsored by Tanta University. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
linagliptin
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT07852546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07852546.